

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

CDK12 Antibody

RRID:AB_2715688

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 11973, RRID:AB_2715688

Antibody Information

URL: http://antibodyregistry.org/AB_2715688

Proper Citation: Cell Signaling Technology Cat# 11973, RRID:AB_2715688

Target Antigen: CDK12

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP

Antibody Name: CDK12 Antibody

Description: This polyclonal targets CDK12

Target Organism: Human, Monkey

Antibody ID: AB_2715688

Vendor: Cell Signaling Technology

Catalog Number: 11973

Alternative Catalog Numbers: 11973S

Record Creation Time: 20231110T033810+0000

Record Last Update: 20260829T055851+0000

Ratings and Alerts

No rating or validation information has been found for CDK12 Antibody.

No alerts have been found for CDK12 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. *Blood*, 145(6), 612.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF?? complex for genomic stability. *Cell reports*, 44(11), 116495.

Polenkowski M, et al. (2023) THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate. *iScience*, 26(1), 105784.

Dieter SM, et al. (2021) Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. *Cell reports*, 36(3), 109394.

Sivakumaren SC, et al. (2020) Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. *Cell chemical biology*, 27(5), 525.

Lv L, et al. (2020) Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. *eLife*, 9.

Iniguez AB, et al. (2018) EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. *Cancer cell*, 33(2), 202.

Wu YM, et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. *Cell*, 173(7), 1770.

Gao Y, et al. (2018) Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. *Cell chemical biology*, 25(2), 135.